Cerebrolysin for Vascular Dementia: A Cochrane Review Finds Hints of Benefit But Very Weak Evidence

This is a Cochrane systematic review (the highest standard of evidence synthesis). The authors searched 12 databases across multiple languages, checked reference lists, and contacted manufacturers. They included all randomized controlled trials of Cerebrolysin in vascular dementia patients. Two reviewers independently selected trials, assessed methodological quality, and extracted data. Meta-analyses used mean differences or standardized mean differences for continuous outcomes and risk ratios for dichotomous outcomes. Evidence strength was assessed using the GRADE framework.

Vascular dementia is the second most common form of dementia worldwide, yet there are essentially no proven treatments. Cerebrolysin is widely used in parts of Asia, Eastern Europe, and Russia despite weak evidence. This Cochrane review — the gold standard for evidence synthesis — delivers a clear verdict: while there are hints of benefit, the supporting evidence is too weak and too biased to justify confident use. The fact that no new trials have been conducted since 2013 suggests a stalled research agenda for a drug that continues to be prescribed to patients.

This review highlights a troubling pattern in dementia therapeutics: drugs being widely prescribed based on weak evidence because no better options exist. Cerebrolysin continues to be promoted and used for vascular dementia despite a Cochrane review explicitly stating the evidence base is weak. The lack of new trials since 2013 suggests commercial use has outpaced scientific validation — a cautionary tale for the neuroprotective peptide field more broadly.

Only 6 small RCTs with 597 total participants were found — far too few for definitive conclusions. All included studies had high risk of bias. Most were conducted in China, Russia, and Romania with industry funding. There was significant heterogeneity in dosing, duration, and follow-up. No studies reported on quality of life or caregiver burden. The GRADE rating of 'very low' means the reviewers have very little confidence that the true effect is close to the estimated effect. No new studies were found since the 2013 review.